News & Updates

Show Multimedia Only

Brensocatib has no impact on COVID-19 clinical outcomes

02 Oct 2022 by

Results of the STOP-COVID trial, presented at ERS 2022, showed no clinical outcome benefit with the dipeptidyl peptidase-1 (DPP-1) inhibitor brensocatib compared with placebo in patients hospitalized with COVID-19 in the UK.

02 Oct 2022

Restricting fluid therapy in septic shock: Yes or no?

01 Oct 2022 by

The administration of restrictive, compared with standard, intravenous (IV) fluid therapy to patients with septic shock in the intensive care unit (ICU) did not result in a reduction in mortality risk, according to results of the CLASSIC* trial.

01 Oct 2022

Add-on, switch-to PEG-IFN therapy strategies improve serological response in CHB patients

30 Sep 2022

Chronic hepatitis B (CHB) patients, who have virological response with long-term entecavir (ETV) treatment, appear to fare well with a strategy of adding or switching to peginterferon (PEG-IFN) therapy, as shown in a study.

30 Sep 2022

Amantadine confers survival benefits on ICU patients with severe COVID-19

29 Sep 2022

Treatment with amantadine appears to lower mortality among COVID-19 patients with severe respiratory failure in the intensive care unit (ICU), a retrospective study has found.

29 Sep 2022

Multiple-dose antibiotic not recommended for preventing infection after breast reconstruction

28 Sep 2022

The use of multiple-dose antibiotic to prevent surgical site infection and implant removal following implant-based breast reconstruction does not appear to be more effective than a single-dose regimen, as shown in a study. In addition, the multi-dose regimen increases the risk of adverse events associated with antibiotic treatment.

28 Sep 2022

FINLAY-FR-1A vaccine boosts natural immunity in COVID-19 convalescents

28 Sep 2022 by

A single dose of FINLAY-FR-1A, a recombinant d-RBD*-based COVID-19 vaccine, strengthens pre-existing natural immunity in patients who have recovered from asymptomatic, mild or moderate COVID-19, and has an excellent safety profile, a phase IIa/b study has shown.